// App-Quantinova.ai

Abstract 13182 : Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis

Researchers

Presenter

  • Filipe A Moura

Principal Investigators

  • Itamar RAZ

  • Avivit Cahn

  • Erica Goodrich

  • Deepak L Bhatt

  • Lawrence A Leiter

  • JOHN WILDING

  • Ingrid A Gause-nilsson

  • Ofri Mosenzon

  • Marc S Sabatine

  • Stephen D Wiviott

Medical Centers

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

  • Hadassah-Hebrew University, Jerusalem, Israel

  • Univ of Liverpool, LIVERPOOL

  • Cardiovascular Medicine, Brigham & Womens Hosp, Boston, MA

  • Brigham & Women's Hospital, Boston, MA

  • HADASSAH HEBREW UNIVERCITY HOSPITAL, Jerusalem, Israel

  • DIABETES MEDICAL CENTER, Tel Aviv, Israel

  • ASTRAZENECA, M Lndal, Sweden

  • Brigham & Women's Hospital, Boston, MA

  • TIMI Study Group, Boston, MA

Locations

  • United States

  • Israel

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Metabolic syndrome

  • Type 2 diabetes mellitus

  • Diabetes

Biomarkers

  • GC Vitamin D Binding Protein

  • Sex hormone binding globulin

  • Body mass index

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved